Leukemia Clinical Trials in Ohio

Showing 441-460 of 1,856 trials

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

NCT02362035

This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.

Follicular Lymphoma (FL)CLLSmall Lymphocytic Lymphoma (SLL)+10 more

Acerta Pharma BV161 participantsStarted Feb 2015

Tucson, Arizona, United States • Los Angeles, California, United States • Denver, Colorado, United States +16 more locations

RECRUITINGPhase 132 miles

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

NCT04780568

This phase Ib trial is to find out the best dose, possible benefits and/or side effects of osimertinib and tegavivint as first-line therapy in treating patients with EGFR-mutant non-small cell lung cancer that has spread to other places in the body (metastatic). Osimertinib and tegavivint may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Metastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8+1 more

Ohio State University Comprehensive Cancer Center24 participantsStarted Jan 2022

Columbus, Ohio, United States

PreviousPage 23 of 93Next

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

Leukemia Trials in Other Cities

MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics

A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia

Study of Oral Food Challenge Biomarkers (SAFER)

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation

UNITY VCS Vitreoretinal Surgery

A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Other Conditions in Ohio